Rates of metabolic syndrome in Queensland adult community mental health consumers with schizophrenia and related disorders: A brief report.
Saved in:
| Title: | Rates of metabolic syndrome in Queensland adult community mental health consumers with schizophrenia and related disorders: A brief report. |
|---|---|
| Authors: | Trott, Mike (AUTHOR), Plever, Sally (AUTHOR), Anzolin, Mellisa (AUTHOR), McCarthy, Irene (AUTHOR), Siskind, Dan (AUTHOR) |
| Source: | Australasian Psychiatry. Aug2025, Vol. 33 Issue 4, p731-735. 5p. |
| Subjects: | Metabolic syndrome, Schizophrenia, Biomarkers, Patient monitoring, Mental health, Regional disparities, Disease prevalence |
| Geographic Terms: | Queensland |
| Abstract: | Objective: People with schizophrenia are at increased risk of metabolic syndrome (MetS), contributing to excess morbidity and mortality. This study examined MetS monitoring rates and prevalence in people with schizophrenia receiving public mental health care in Queensland. Methods: Data from the Consumer Integrated Mental Health and Addiction Application (CIMHA) were extracted for individuals aged 18–64 with a schizophrenia diagnosis. MetS was determined using International Diabetes Federation criteria. Results: Of 5802 individuals, 16.0% had sufficient data to determine MetS status. Among those with complete data, MetS prevalence was 53.2%. MetS was significantly more common in regional than metropolitan areas. Blood pressure and BMI were recorded for most patients (≥74%), but biochemical indices (fasting glucose, HDL, triglycerides) were recorded in only 26.4%–35.5%. Conclusions: MetS is highly prevalent in schizophrenia, yet routine monitoring is incomplete, particularly for biochemical markers. Strengthening data integration across healthcare systems and ensuring access to evidence-based interventions for MetS management, particularly in regional areas, is critical to addressing this major health disparity. [ABSTRACT FROM AUTHOR] |
| Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective: People with schizophrenia are at increased risk of metabolic syndrome (MetS), contributing to excess morbidity and mortality. This study examined MetS monitoring rates and prevalence in people with schizophrenia receiving public mental health care in Queensland. Methods: Data from the Consumer Integrated Mental Health and Addiction Application (CIMHA) were extracted for individuals aged 18–64 with a schizophrenia diagnosis. MetS was determined using International Diabetes Federation criteria. Results: Of 5802 individuals, 16.0% had sufficient data to determine MetS status. Among those with complete data, MetS prevalence was 53.2%. MetS was significantly more common in regional than metropolitan areas. Blood pressure and BMI were recorded for most patients (≥74%), but biochemical indices (fasting glucose, HDL, triglycerides) were recorded in only 26.4%–35.5%. Conclusions: MetS is highly prevalent in schizophrenia, yet routine monitoring is incomplete, particularly for biochemical markers. Strengthening data integration across healthcare systems and ensuring access to evidence-based interventions for MetS management, particularly in regional areas, is critical to addressing this major health disparity. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10398562 |
| DOI: | 10.1177/10398562251358760 |
